The treatment specifically targets the tumor microenvironment in the MC38 murine colon cancer model, promoting the induction of tumor antigen‐specific T cells. It restores the activity of dendritic cells (DCs) in tumor tissues, inhibits STAT3 transcription activity in CD11c + DCs, and modulates the expression of immune‐related markers on DCs, such as CD83 and PD‐L1. Here, CD83 is linked to colonic neoplasm.